medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma

Sawanyawisuth K, Tantapotinan N, Kraiklang R, Puapairoj A, Wongkham C, Riggins GJ, Wongkham S

Language: English
References: 34
Page: 71-81
PDF size: 433.91 Kb.


ABSTRACT

Background and aim. Trophoblast cell surface antigen 2 (TROP2) or tumor-associated calcium signal transducer 2 (TACSTD2) is a 36-kDa type I transmembrane glycoprotein and exerts dual functions as an oncogene and tumor suppressor in cancer cells. In this study, we investigated the expression and functions of TROP2 in liver fluke-associated cholangiocarcinoma (CCA). Material and methods. TROP2 expression in 85 CCA tissues was detected by using immunohistochemistry. The methylation status of TROP2 promoter was studied in 15 matched pairs of normal and CCA formalin fixed paraffin embedded (FFPE) tissues using the bisulfite genomic sequencing (BGS) method. The functions of TROP2 on cancer cell behavior were investigated using siRNA in CCA cell lines. Proliferation, migration and invasion assays were performed. A PCR array was used to evaluate the impact of TROP2 knockdown on the gene expression profiles. Results. TROP2 was highly expressed in all normal bile duct epithelia, but significantly down-regulated in CCA cells. Sixty percent of CCA revealed promoter hypermethylation compared to the corresponding adjacent normal tissues. TROP2 knockdown significantly enhanced the proliferation and migration in CCA cell lines, and altered the expressions of MARCK, EMP1 and FILIP1L. Conclusion. We provide new evidence that TROP2 is epigenetically down-regulated and operates as a negative regulator of cell proliferation and migration in liver fluke-associated CCA.


REFERENCES

  1. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-5.

  2. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186-91.

  3. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62: 152-8.

  4. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12: 3057-63.

  5. Ibragimova I, Ibanez de Caceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, et al. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) 2010; 3: 1084-92.

  6. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66: 7490-501.

  7. Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med 2012; 4: 472-85.

  8. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006; 3: e486.

  9. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 2011; 59: 701-10.

  10. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008; 7: 280-5.

  11. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, Wiangnon S, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma—focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 2010; 11: 1159-66.

  12. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007; 4: e201.

  13. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.

  14. Ning S, Guo S, Xie J, Xu Y, Lu X, Chen Y. TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg 2013; 17: 360-8.

  15. Kidoikhammouan S, Seubwai W, Tantapotinan N, Silsirivanit A, Wongkham S, Sawanyawisuth K, Wongkham C. TNP-470, A Methionine Aminopeptidase-2 Inhibitor, Inhibits Cell Proliferation, Migration and Invasion of Human Cholangiocarcinoma Cells In Vitro. Asian Pac J Cancer Prev 2012; 13 Suppl.: 155-60.

  16. Wang L, Hirayasu K, Ishizawa M, Kobayashi Y. Purification of genomic DNA from human whole blood by isopropanolfractionation with concentrated Nal and SDS. Nucleic Acids Res 1994; 22: 1774-5.

  17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.

  18. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9: 253.

  19. Cai WK, Sima H, Chen BD, Yang GS. Risk factors for hilar cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2011; 17: 249-53.

  20. Tao LY, He XD, Qu Q, Cai L, Liu W, Zhou L, Zhang SM. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 2010; 30: 215-21.

  21. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24: 127-37.

  22. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-14.

  23. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.

  24. Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently overexpressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14: 2501-10.

  25. Masaki T, Tokuda M, Yoshida S, Nakai S, Morishita A, Uchida N, Funaki T, et al. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 2005; 26: 661-71.

  26. Techasen A, Loilome W, Namwat N, Takahashi E, Sugihara E, Puapairoj A, Miwa M, et al. Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci 2010; 101: 658-65.

  27. Taylor V, Welcher AA, Program AE, Suter U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J Biol Chem 1995; 270: 28824-33.

  28. Gnirke AU, Weidle UH. Investigation of prevalence and regulation of expression of progression associated protein (PAP). Anticancer Res 1998; 18: 4363-9.

  29. Wang HT, Kong JP, Ding F, Wang XQ, Wang MR, Liu LX, Wu M, et al. Analysis of gene expression profile induced by EMP-1 in esophageal cancer cells using cDNA Microarray. World J Gastroenterol 2003; 9: 392-8.

  30. Zhang J, Cao W, Xu Q, Chen WT. The expression of EMP1 is downregulated in oral squamous cell carcinoma and possibly associated with tumour metastasis. J Clin Pathol 2011; 64: 25-9.

  31. Hu Y, Mivechi NF. Promotion of heat shock factor Hsf1 degradation via adaptor protein filamin A-interacting protein 1- like (FILIP-1L). J Biol Chem 2011; 286: 31397-408.

  32. Mazzanti CM, Tandle A, Lorang D, Costouros N, Roberts D, Bevilacqua G, Libutti SK. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res 2004; 14: 1585-93.

  33. Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 2005; 30: 347-58.

  34. Kwon M, Hanna E, Lorang D, He M, Quick JS, Adem A, Stevenson C, et al. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res 2008; 68: 7332-41.




2020     |     www.medigraphic.com